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Background: Hormonal manipulation is sometimes recommended in the treatment of metastatic endometrial
stromal sarcoma, but there are few data assessing the efficacy of endocrine therapies in this subtype of uterine
sarcomas.
Methods: We performed a retrospective electronic medical record review of patients with metastatic ESS treated
with a hormonal agent at Royal Marsden Hospital between 1999 and 2011. We assessed progression-free survival
(PFS), objective response and toxicity profile among patients with measurable disease.
Results: Thirteen patients with metastatic ESS were treated with hormonal therapies. Hormone receptor status
(estrogen and progesterone receptors) was assessed in 9 out of 13 patients and in all of them it was moderately to
strongly positive. Aromatase inhibitors (AIs) were prescribed as first endocrine line in 11/13 patients and progestins
in the remainder, while in 2nd line treatment AIs were prescribed in 7/10 patients, followed by progestins and GnRH
analogues. Median PFS for 1stline was 4.0 years (95% CI: 2.4 – 5.5 years) with 5-year progression-free rate of 30.8%
(95% CI: 5.7 – 55.9%), both of which reflect the indolent natural history of ESS. Best objective response was partial
response (PR) in 6/13 patients (46.2%; 95% CI: 19.2 – 74.9) and clinical benefit rate (defined as complete
response + PR + stable disease ≥6 months) was 92.4% (95% CI: 64.0 – 99.8%; 12/13 patients). Median PFS for 2nd line
was 3.0 years (95% CI: 2.0 – 4.1 years) with 2-year progression-free rate of 88.9% (95% CI: 68.3 – 100.0).
Conclusions: In this cohort of metastatic ESS patients, 1st line endocrine treatment achieved objective response in
46.2% of them and clinical benefit in 92.4%. Tamoxifen and hormone replacement therapy should not be
prescribed in patients with ESS due to their detrimental effects. Until more solid data are available, a reasonable
recommendation would be that 1st line treatment with an endocrine treatment, preferably with an AI. Moreover, in
view of the positive outcomes of our patients that received 2nd/3rdline endocrine treatments, all available hormonal
options should be used in sequence in the management of ESS.
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Endometrial stromal sarcoma (ESS) accounts for less
than 10% of all uterine sarcomas, and is characterised by
an indolent natural history, with a 5-year disease-specific
survival of approximately 90% for stages I–II and 50%
for advanced stages III–IV [1]. However, even in early
stages an almost 50% recurrence rate has been* Correspondence: eirini.thanopoulou@nhs.net
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unless otherwise stated.documented [2]. All ESS are low grade according to
current terminology [1].
The mainstay of treatment of localized ESS is total
abdominal hysterectomy (TAH) with bilateral salpingo-
oophorectomy (BSO) [1]. There is no established adjuvant
treatment, though endocrine treatment has increasingly
been recommended [1,3]. For women with recurrent ad-
vanced unresectable ESS, systemic hormonal treatment is
recommended with palliative intent; several lines of
endocrine treatment combined with interval cytoreduc-
tive surgery may significantly prolong overall survivalentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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estrogen deprivation, patients may be treated with
chemotherapy, with less favourable outcomes [4,5].
ESS is well known to be hormonal receptor positive
[1]; in the literature, estrogen receptor (ER) expression
ranges between 40-100% [4,6,7] and progesterone recep-
tor (PgR) between 60-100% [4,6,7]. As such, hormonal
treatments resulting a reduction in estrogen drive have a
leading role in therapeutic management, and appear to
be more effective than chemotherapy [1,4]. Although the
predictive role of ER and PgR has not been fully estab-
lished in ESS yet, hormonal treatments have shown
significant and durable responses in the metastatic set-
ting and prolonged disease free survival in the adjuvant
setting [1,3].
Due to the rarity of ESS, most of the data derive from
case reports, with the bias that positive outcomes are
more likely to be published [8-10] or small retrospective
studies [4,6,7,11,12], which are characterised by small
sample size with patients treated over a long period of
time, both leading to marked heterogeneity in patient
characteristics and interpretation of outcomes. Most of
the data refer to progestins as they were first used to
treat ESS, while currently aromatase inhibitors (AIs) are
preferred as 1st line due to the higher therapeutic index,
or as 2nd line in progestin-resistant disease [1]. With
this in mind, we sought to record our institution’s
experience in treating ESS patients with endocrine
treatments.
Methods
We performed a retrospective electronic medical record
review of patients with advanced or recurrent ESS
treated with hormonal manipulation on the Sarcoma
Unit of the Royal Marsden Hospital (RMH) from Janu-
ary 1999 to July 2011. Patients were identified using the
prospective Sarcoma Unit database and confirmed by
pharmacy records. Patients were excluded if they had re-
ceived any hormonal treatment to treat other diseases,
such as breast cancer or had received concomitant
chemotherapy. Patients’ electronic medical records were
reviewed for age at diagnosis, stage, sites of metastases,
volume of metastatic disease, tumour grade, hormone
receptor status (ER and PgR), performance status, prior
treatments, type and dose of hormonal agent used and
toxicities. In addition, we recorded the presence or
absence of co-morbidities.
All patients had surgical biopsies reviewed by the RMH
department of pathology, which confirmed the diagnosis
of ESS. Tumours were diagnosed as “low-grade” according
to current terminology [13]. Immunohistochemistry for
ER and PgR was performed on formalin fixed, paraffin
embedded, representative, whole sections of tumour.
Deparaffinized tumour sections were stained for ER andPgR (both supplied prediluted from Ventana Systems UK
Ltd, Salisbury, UK) using heat-induced epitope retrieval.
Appropriate positive and negative controls were used
throughout.ER and PgR status was determined semiquan-
titatively and assigned as ‘weak’, ‘moderate’ or ‘strong’ in
tumour nuclei.
The primary end-point of the analysis was progression-
free survival (PFS), defined as time from the start of
hormonal treatment until disease progression or death.
Patients who had reached neither endpoint were censored
at date of last follow-up. Hence, PFS1 was defined as time
from the start of 1st line hormonal treatment until disease
progression or death and PFS2 was defined as time from
the start of 2nd hormonal treatment until disease progres-
sion or death. The Kaplan–Meier method was used to
estimate PFS. Objective response rate (ORR), defined as
the rate of a complete response (CR) or partial response
(PR) and clinical benefit rate (CBR), as the rate of CR, PR,
and stable disease (SD) for at least 6 months wereevalu-
ated by Response Evaluation Criteria in Solid Tumours
(revised RECIST guideline, version 1.1) criteria [14].
Toxicity was graded using the National Cancer Institute
Common Terminology Criteria for Adverse Events
(CTCAE) version 4.02.
The study was approved by the Committee for Clinical
Research of RMH.
Results
Patient and tumour characteristics
We identified 22 patients with locally recurrent and/or
metastatic ESS treated with hormonal manipulation
from January 1999 to December 2011. We excluded 9
cases that were either treated in another institution or
presented as second opinion to our unit or which did
not have sufficient clinical date for assessment. The
demographics, tumour characteristics and prior surgical
and radiotherapy treatment details of the remaining 13
patients are listed in Table 1. The median age at time of
initiation of 1st line hormonal treatment was 49 years
(range 39 to 70). All but one patient were postmeno-
pausal at the time of 1st line treatment (92%).
ER status was determined semi-quantitatively in 9/13
patients, and assigned as ‘weak’, ‘moderate’ or ‘strong’ in
tumour nuclei. All nine patients had moderate to strong
(grade 2–3) ER and PgR positive tumours.
All patients had measurable disease at time of initi-
ation of 1st line hormonal treatment. All but one patient
had high volume disease, which was defined as the pres-
ence of any tumour deposit >2 cm in longest diameter
on radiographic imaging [15]. Moreover, 5 patients had
oligometastatic disease defined as the presence of ≤5
metastatic deposits, while the other 8 patients had mul-
tiple metastases. Sites of disease included pelvis in 6
patients (46.2%), extrapelvic disease in 3 (23%) and both
Table 1 Patient and tumour characteristics (n = 13)
Variable (n = 13) N (%)









Initial management at diagnosis
Surgical resection alone 5 (38.5%)




Prior pelvic radiotherapy 4 (30.8%)
Sites of metastases at time of 1st line
Pelvic 6 (46.2%)
Extrapelvic 3 (23%)
Both pelvic and extrapelvic disease 4 (30.8%)
Tumour volume at 1st line
Low 1 (7.7%)
High 12 (92.3%)





Moderate to strong (grade 2–3) 9 (69.2%)
Weak (grade 1) 0 (7.1%)
NA 4 (30.8%)
PgR
Moderate to strong (grade 2–3) 9 (69.2%)
Weak (grade 1) 0 (7.1%)
NA 4 (30.8%)
BSO, bilateral salphigoophorectomy; HRT, hormonal replacement therapy; ER,
estrogen receptor; PgR, progesterone receptor NA, not available.
Table 2 Endocrine treatments details (n = 13)
1st line (n = 13) N (%) median (range)
Median age at 1st line hormonal treatment 49 years (39–70)
Type of 1st line hormonal treatment
NSAI 11 (84.6%)
Progestins 2 (15.4%)
Response to 1st line
Complete response 0 (0%)
Partial response 6 (46.2%)
Stable disease (more than 6 months) 6(46.2%)
Progressive disease 1(7.6%)
2nd line (n = 10)
Median age at 2nd line hormonal treatment 59 years (43–72)




GnRH analogue 1 (10%)
Response to 2nd line
Complete response 0 (0%)
Partial response 0 (0%)
Stable disease (more than 6 months) 10(100%)
Progressive disease 0 (0%)
NSAI, non-steroidal aromatase inhibitor; GnRH, gonadotropin-releasing hormone.
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(30.8%).
Seven patients (54%) received hormonal replacement
therapy (HRT) either after surgery or to alleviate post-
menopausal symptoms, with median duration of treat-
ment 3.6 years (1.3 months −14 years; Table 1). Five of
these patients were on HRT at the time of diagnosis of
metastatic disease. One patient stopped HRT as initialhormonal manipulation and had partial response of her
metastatic ESS that lasted 48 months; she was subse-
quently treated with letrozole and is still in remission
(PFS 126 months). The other 4 patients stopped HRT
and at the same time were started on 1st line endocrine
treatment with an AI with subsequent regression of
disease. Two out of the 13 patients were treated with
tamoxifen at the time of diagnosis of metastatic ESS
(duration of treatment 3 and 5 years respectively), and 1
patient was treated both with tamoxifen and HRT prior
to developing metastatic ESS, further supporting previ-
ous findings [7]. All of them were started on 1st line
treatment.
As shown in Table 2, non-steroidal AIs (NSAIs),
namely letrozole 2.5 mg and anastrozole 1 mg daily,
were given to 11/13 patients (84.6%), while 2/13 patients
(15.4%) were treated with progestins. Of note, one of the
patients was switched from megestrol acetate (MA) to
letrozole because of allergic reaction to MA. Nine pa-
tients (69.3%) received hormonal manipulation as 1st
line treatment without receiving any prior endocrine
or chemotherapeutic agent prior to AI. Three patients
were started on 1st line endocrine treatment as they
progressed on 1st line chemotherapy, while the 4th pa-
tient was started on endocrine treatment (progestin) as
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chemotherapy.
In the 2nd line setting (Table 2), the majority of pa-
tients were treated with AIs, either NSAIs (4/10 patients,
40%) or exemestane, an irreversible steroidal AI (3/10
patients, 30%). The other 2 patients received progestins
and one patient (premenopausal) was treated with goser-
elin. All patients had progressed after 1st line endocrine
treatment and had measurable disease at time of 2nd
line AI treatment; only one patient was lost in follow-up.
Finally, 2 patients that eventually progressed on 2nd line
endocrine treatment were treated with 3rd line of hor-
monal agents, specifically exemestane and letrozole.
Objective responses to all lines of endocrine treatments
With a median follow-up of 7.8 years, the median dur-
ation of 1st line endocrine treatment was 48 months
(range 5–126 months). No patient achieved a CR, while
PR was observed in 6 patients (46.2%), thus accounting
for an ORR of 46.2% (95% CI: 19.2 – 74.9). All patients
had high volume of disease, with only one of them hav-
ing oligometastatic disease. The ER and PgR status was
available in only 3/6 patients and in all 3 of them both
were moderately to strongly positive. One patient is still
on 1st line endocrine treatment (94 months), but four
patients eventually progressed and all of them were
offered 2nd line endocrine treatment, in view of the
prolonged PFS and acceptable side effect profile. One
patient was lost in follow-up.
Six patients (46.2%) had SD as best response, with all
of them maintaining it for more than 6 months. All but
one patient had high volume of disease, and 3/6 patients
had oligometastatic disease. The ER and PgR status was
available in 5 patients and in all of them expression of
both was moderately to strongly positive. Of those pa-
tients that achieved SD, as best response, one patient is
still on 1st line endocrine treatment (126 months), but
the other five patients eventually progressed and all of
them were offered 2nd line endocrine treatment. Of note,
one of these patients stopped her 1st line treatment
(letrozole) after 49 months, but her disease recurred
42 months later. Overall, the CBR (CR + PR + SD >
6 months) was 92.4% (95% CI: 64.0 – 99.8%). Finally,
best response was progression of disease (PD) in one pa-
tient, who had high volume pelvic recurrence; hence she
had debulking surgery after which she was started on
2nd line endocrine therapy with medroxyprogesterone.
Her disease was moderately ER and PgR positive.
The median duration of 2nd line endocrine therapy
was 21.6 months (range 11–47 months). All patients
achieved SD as best response, with all of them maintain-
ing it for more than 6 months. All but one patient had
high volume of disease, and three of them had oligome-
tastatic disease. The ER and PgR status was available in7/10 patients and in all them both receptors’ status was
moderately/ strongly positive. Overall, four of these pa-
tients are continuing their AI treatment to date (11–47
months), a patient progressed and has been referred for
palliative care, two patients were switched to 3rd line
endocrine treatment, one was treated with sirolimus,
one received 2 lines of chemotherapy, and one patient
died with disease progression. With regards to the two
patients that received 3rd line endocrine treatment, one
patient achieved SD for 10 months, while the other pa-
tient stopped treatment before full reassessment of her
disease response.
Progression-free survival
At last follow-up, 3 out of 13 patients (23%) had died
with disease progression, 1 patient (7.7%) was alive with
disease progression (palliative care), 2 (15.4%) were alive
on 1st line letrozole without progression, 4 (30.8%)
patients were alive on 2nd line AI (letrozole and exemes-
tane), 2 (15.4%) were alive on 3rd line endocrine treat-
ment and 1 patient was lost in follow-up.
Median PFS for 1st line endocrine treatment (PFS1)
was 4.0 years (95% CI:2.4 – 5.5 years; Figure 1a). The
2-year progression-free rate was 76.9% (95% CI:54.0 –
99.8%) and the 5-year progression-free rate 30.8% (95%
CI:5.7 – 55.9%). Median PFS for 2ndendocrine treat-
ment (PFS2) was 3.0 years (95% CI:2.0 – 4.1 years;
Figure 1b). The 2-year progression-free rate was 88.9%
(95% CI:68.3 – 100.0).
Toxicities during aromatase inhibitor treatment - any
dose reduction/ discontinuation
Toxicities observed during 1st line treatment with AIs
included only grade 1–2 side effects; specifically, grade 1
hot flushes in 2 patients, grade 2 arthralgias in one pa-
tient, grade 1 headache in one patient and grade 1 rash
in another. The toxicity profile of progestins included
only an allergic reaction to MA; hence the patient was
switched to letrozole.
Similarly in the 2nd line setting, only grade 1 hot
flushes and joint pain was recorded in 1 out of 7 patients
on AIs, while in the 3rd line the main toxicities reported
were osteoporosis in one patient that was started on
supplementation treatment and grade 2–3 mood changes
in another patient. With regards to progestins (MA), one
patient developed significant weight gain and eventually
stopped treatment.
Discussion
Endometrial stromal sarcoma (ESS) is considered a
hormone-dependent malignancy, however due to its rar-
ity there are no prospective randomised studies on hor-
monal agents, data consisting instead of case reports and
small retrospective series [1,16]. The rationale for using
Figure 1 Progression Free Survival (PFS). In Figure 1a is depicted the PFS defined as date of start of first line treatment to date of progression
or death (PFS1), while in Figure 1b is depicted the PFS defined as date of start of second line treatment to date of progression or death (PFS2).
Surviving progression free patients are censored at last follow up.
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view of the hormone receptor expression and low grade;
hence, the hormonal strategies are mainly extrapolated
from experience in treating hormone-positive breast
cancer, which is much more common [1]. Progestins
were among the first hormonal modulators to be ex-
plored in the management of ESS, followed eventually
by 3rd generation AIs, which are currently the preferred
hormonal agents for 1st line treatment or 2nd line treat-
ment in progestin-resistant ESS [1].
This case series adds to the current knowledge of the
role of hormonal agents in the management of patients
with ESS. In our cohort of 13 patients, with measurable
advanced ESS, objective response was observed in 46.2%
(all patients had PRs and were on AIs), and clinical
benefit rate in 92.4% of patients. The only patient that
progressed was moderately ER and PgR positive with
high volume of disease. This high response rate is in ac-
cordance with published data [1,4,16] on 1st line treat-
ment of ESS with progestins [4,16], and add to the
sparse data on 1st line treatment with AIs [1]. Median
PFS (PFS1) was 4.0 years (95% CI:2.4 – 5.5 years) with
5-year progression-free rate of 30.8% (95% CI:5.7 –
55.9%), both of which reflect efficacy of estrogen
deprivation and the indolent natural history of ESS.
To our knowledge, this is the first case series of ad-
vanced ESS reporting outcomes of 2nd line endocrine
treatment. In our cohort of 10 patients, all but one of
which had a high volume of metastatic disease, no ob-
jective response was observed. However, all patients ex-
hibited stable disease for more than 6 months. Median
PFS (PFS2) was 3.0 years (95% CI:2.0 – 4.1 years) with
2-year progression-free rate of 88.9% (95% CI:68.3 –
100.0). Moreover, we report for the first time two
patients with metastatic ESS that were treated with 3rd
line endocrine treatment. Hence, the optimal treatmentstrategy in advanced ESS would appear to be cytoreduc-
tive surgery followed by sequential lines of hormonal
agents [1,6,17].
As expected, all hormonal treatments had a favourable
toxicity profile with mainly grade 1–2 side effects. Not-
able is an allergic reaction to MA, for which the patient
was switched to letrozole and significant weight gain on
MA by another patient, who eventually stopped treat-
ment. Moreover, one patient on exemestane developed
osteoporosis and was started on bisphosphonates.
Finally, the detrimental effect of HRT and tamoxifen
has been shown in this cohort, as 7/13 patients received
prolonged HRT (duration of HRT 6–168 months) and
3/13 patients were treated with tamoxifen at the time of
diagnosis of metastatic ESS; disease responses were
observed with withdrawal of these treatments, further
supporting previous findings [6,7]. The 2014 update of
NCCN and ESMO guidelines have incorporated the
contraindication of tamoxifen and HRT in patients with
ESS [18,19].
The main limitations of this study are its retrospective
nature and the small number of patients, which reflect
the rarity of this subset of uterine sarcomas. Hence, the
results should be interpreted cautiously. Most literature
data to date refer to the use of progestins as 1st line
endocrine treatment with Cheng et al. showing in the
largest cohort (30 patients) that hormonal treatment was
more effective than radiotherapy and chemotherapy [4].
Until prospective studies provide mature data, it is
reasonable to recommend that the 1st line treatment of
ESS should comprise an endocrine agent, preferably an
AI [1,19].
Conclusions
ESS is clearly a hormone sensitive subtype of uterine sar-
comas with an indolent natural history and significant
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Thus, all available hormonal options should be used in
sequence for the management of ESS. Moreover, the
adverse effects of tamoxifen and HRT have been
highlighted and their use is contraindicated in patients
diagnosed with ESS [1,6,7]. Our cohort adds to the lim-
ited data available for the management of ESS [1]. It re-
mains to be clarified if the favourable outcomes shown
in our study are driven predominantly by the favourable
biology of ESS, and to quantify any correlation between
hormonal receptor expression and response to endocrine
treatment, similar to that seen in hormone positive
breast cancer [1,11].
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